TEM Tempus AI, Inc.

Mentions (47)

• Newszacks.com·22h ago·Negative

  Here's How Tempus AI is Capitalizing on AI-ECG Market Growth TEM is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardiac conditions.

  View source ↗
• Newsbusinesswire.com·5d ago·Neutral

  Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026 CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. At this year's congress, Tempus will showcase clinical research revealing insights in cancer biology, treatment response and patient outcomes across solid…

  View source ↗
• 4chan /biz/biz·7d ago·Negative

  >>62735271 Not buying anything for the next 2 weeks will comparatively make you more than most investments. Once the cheapies appear and pink wojaks flood the catalogue, when smiggers are suiciding in their droves only then I will be slurping: MU, SNDK, NVDA, WDC, RDDT, META, AVGO, TSMC, NBIS, SKHY, BLOOM, ARM, PENG, GRRR, GRAB, CRDO, SMCI, TEM, POET

  View source ↗
• News (RSS)seekingalpha·7d ago·Positive

  Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike

  View source ↗
• News (RSS)fool·11d ago·Negative

  Tempus AI Chief Accounting Officer Sells $529,650 of Stock Sale follows 30% rebound in the stock year to date.

  View source ↗
• Newsnewsfilecorp.com·12d ago·Neutral

  TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations Highlights TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin A…

  View source ↗
• News (RSS)yahoo·13d ago·Neutral

  Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test

  View source ↗
• News (RSS)seekingalpha·13d ago·Neutral

  Tempus AI: High Risk, But With A Great Cause

  View source ↗
• Newsseekingalpha.com·14d ago·Negative

  Tempus AI: High Risk, But With A Great Cause Tempus AI remains a Buy as I increase my position, driven by strategic moves and accelerating growth. TEM's acquisition of Personalis fills a critical MRD monitoring gap, unlocking recurring revenue and enhancing AI data assets. Q2 2026 saw 22% revenue growth, improved margins, and raised full-year guidance, despite continued operating losses.

  View source ↗
• News (RSS)seekingalpha·14d ago·Neutral

  Tempus AI: Data And Applications Will Unlock More Upside

  View source ↗
• Newsseekingalpha.com·14d ago·Positive

  Tempus AI: Data And Applications Will Unlock More Upside Tempus AI remains a buy after a 60% rally, driven by robust oncology testing volumes and expanding data & applications revenue. Q2 oncology testing volumes grew 31% YoY, with MRD test volumes nearly doubling since Q4 2025, validating the Personalis acquisition. Data & applications segment led Q2 growth at 28%, with strong bookings and AI innovation positioning the company for long-term growth and margin expansion.

  View source ↗
• Newsmarketbeat.com·14d ago·Positive

  Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion Tempus AI NASDAQ: TEM Founder and CEO Eric Lefkofsky said the company's second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business.

  View source ↗
• News (RSS)seekingalpha·14d ago·Neutral

  Tempus AI: Market Is Hyping On An Uncertain Number

  View source ↗
• Newsinvezz.com·18d ago·Positive

  Tempus AI stock is soaring: does it have more upside to go? Tempus AI stock continues its strong bull run and is now trading at its highest level since November last year. TEM jumped to $80, up 95% from its lowest level this year, with market capitalization above $14 billion.

  View source ↗
• Newszacks.com·18d ago·Neutral

  Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength? Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  View source ↗
• Newsyoutube.com·21d ago·Neutral

  Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AI Eric Lefkofsky, Tempus AI founder and CEO, joins 'The Exchange' to discuss AI's role in healthcare, advancing cancer research with AI, personalized vaccines, and more.

  View source ↗
• News (RSS)investing·24d ago·Neutral

  Tempus AI plans 100,000 whole genome sequencing dataset

  View source ↗
• Newsbusinesswire.com·25d ago·Positive

  …us Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically …

  View source ↗
• News (RSS)barrons·32d ago·Neutral

  The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.

  View source ↗
• News (RSS)wsj·32d ago·Neutral

  The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.

  View source ↗
• News (RSS)yahoo·33d ago·Neutral

  Tempus AI Got an $80 Target and 28% Upside Call. Is Wall Street Underestimating Its Healthcare Data Moat?

  View source ↗
• News (RSS)investing·34d ago·Positive

  Tempus AI stock rises on Piper Sandler upgrade to Overweight

  View source ↗
• Newsdefenseworld.net·38d ago·Neutral

  Artificial Intelligence Stocks To Follow Today – August 27th Tempus AI, Hut 8, SentinelOne, SoundHound AI, Upstart, Fluence Energy, and BigBear.ai are the seven Artificial Intelligence stocks to watch today, according to MarketBeat's stock screener tool. Artificial intelligence stocks are shares of publicly traded companies that develop, provide, or significantly use AI technologies, such as machine learning, generative AI, robotics, or related hardware and

  View source ↗
• News (RSS)yahoo·39d ago·Neutral

  Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

  View source ↗
• News (RSS)zerohedge·39d ago·Neutral

  …unvaccinated. Bogen and her department did say that not all deaths are referred to a coroner under Pennsylvania law. A thin-section transmission electron micrograph (TEM) reveals the ultrastructural appearance of a single virus particle, or "virion", of measles virus. CDC via Getty Images State law says that any deaths "known or suspected to be due to contagious disease and constituting a public hazard" shall be investigated by a coroner. State officials also encouraged people to take the measle…

  View source ↗
• Newsbenzinga.com·42d ago·Neutral

  What's Going On With Tempus AI Stock on Monday? Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.

  View source ↗
• News (RSS)seekingalpha·44d ago·Positive

  Tempus AI: Winning With Precision Medicine

  View source ↗
• News (RSS)yahoo·44d ago·Neutral

  What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing

  View source ↗
• News (RSS)yahoo·44d ago·Neutral

  Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened

  View source ↗
• News (RSS)fool·44d ago·Positive

  Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know Bartolucci disposed of shares valued at $306,342 to cover statutory withholding obligations tied to RSU vesting, retaining direct holdings of 67,866 shares worth $3.35 million.

  View source ↗
• News (RSS)yahoo·44d ago·Neutral

  Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter.

  View source ↗
• News (RSS)fool·44d ago·Negative

  What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing This non-discretionary sale to cover RSU withholding obligations reduced his direct stake, but he retains about 106,000 shares valued at $6.49 million.

  View source ↗
• News (RSS)fool·44d ago·Neutral

  Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened These sales were driven by tax withholding obligations tied to restricted stock unit vesting under a pre-established trading plan.

  View source ↗
• News (RSS)fool·44d ago·Neutral

  Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter. This sale was non-discretionary, executed to cover tax withholding from RSU vesting.

  View source ↗
• News (RSS)fool·44d ago·Neutral

  Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know This filing details a non-discretionary sale that reduced Lefkofsky's direct holdings by a small percentage.

  View source ↗
• Newsseekingalpha.com·45d ago·Positive

  Tempus AI: Winning With Precision Medicine Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Recent cancer vaccine developments from Merck and Moderna reinforce the strategic relevance and growth runway for TEM's platform. The company already had strong momentum with higher test ASPs, with the cancer tests a huge bonus.

  View source ↗
• Newsfool.com·45d ago·Neutral

  A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know The transaction involved 3,000 shares with a value of $161,700 on August 14. The sale reduced West's direct equity position by 8%.

  View source ↗
• Newsfool.com·45d ago·Positive

  Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade Polovin executed the sale of 30,075 shares between August 18 and August 19, generating approximately $1.5 million in proceeds. The transaction was non-discretionary and performed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

  View source ↗
• Newsfool.com·45d ago·Neutral

  Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know These 6,175 shares were disposed of at a weighted average price of $49.61 per share, for a total transaction value of $306,342. The transaction was a "sell to cover" event executed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

  View source ↗
• Newsfool.com·45d ago·Neutral

  What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing The transaction involved 48,842 shares with an estimated value of about $2.7 million. This was a non-discretionary transaction executed to cover tax withholding obligations associated with the vesting of restricted stock units.

  View source ↗
• Newsfool.com·45d ago·Negative

  Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened The transactions involved 17,314 shares at a weighted average price of $53.71 per share, totaling $930,000. The sales were executed directly by Schoenherr and were primarily structured to satisfy tax withholding obligations.

  View source ↗
• Newsfool.com·45d ago·Neutral

  Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter. The transaction involved 41,095 shares executed at a weighted average price of $49.61 per share, representing a total value of $2.0 million. The sale was non-discretionary, executed to cover tax obligations associated with the vesting of restricted stock units, and does not reflect the insider's view on the stock.

  View source ↗
• Newsfool.com·45d ago·Positive

  Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know The disposition of 133,000 shares was executed at a weighted average price of $49.61 per share, representing a total transaction value of about $6.6 million. The activity was non-discretionary, performed solely to satisfy statutory tax withholding obligations associated with the vesting of restricted stock units.

  View source ↗
• Newsseekingalpha.com·49d ago·Neutral

  Tempus AI: The Data Flywheel Has Started Spinning Tempus AI reported its first GAAP profit, accelerated data business growth, and raised 2026 revenue guidance to $1.595B–$1.605B (+25% Y/Y). Operating leverage from oncology volume and a mix shift to high-margin Data & Apps (72%-75% GM) drove profitability improvement and narrowed cash outflows. FDA approval for xT CDx and higher xF liquid biopsy ASPs is expected to add ~$400M incremental revenue by 2028, with the Personalis acquisition targeting …

  View source ↗
• Newsnewsfilecorp.com·49d ago·Negative

  TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies Agreement transitions previously announced LOI into a definitive commercial relationship First bulk commercial order fulfilled for distribution into clinics and pharmacies TempraMed expands access to its temperature-protection solutions through healthcare channels in Panama Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd…

  View source ↗
• Newszacks.com·54d ago·Positive

  Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

  View source ↗
• Newszacks.com·55d ago·Positive

  Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.

  View source ↗